Co-Diagnostics Earnings Call: Progress Amid Funding Strain

Co-Diagnostics ((CODX)) has held its Q1 earnings call. Read on for the main highlights of the call.

Co-Diagnostics’ latest earnings call painted a picture of solid operational momentum set against a challenging financial backdrop. Management highlighted major strides in clinical programs, manufacturing build‑out and international expansion, yet also acknowledged minimal current revenue, negative margins, widening losses and shrinking cash, leaving investors weighing long‑term potential against near‑term funding risk.

Revenue Growth Year-over-Year

Co-Diagnostics reported Q1 2026 revenue of $146,000, nearly tripling from $50,000 a year earlier and signaling early commercial traction across its test portfolio. However, management stressed that the absolute revenue base remains very small, underscoring how dependent the investment case is on future product launches rather than current sales.

Upper Respiratory Clinical Enrollment Completed

The company completed enrollment of over 1,400 patients in its upper respiratory multiplex study, a key step toward its first 510(k) and CLIA‑waived point‑of‑care clearance. Based on the available data, management plans an initial Q3 2026 filing focused on Flu A, Flu B and RSV, with COVID to be added later if epidemiology and data support it.

India Regulatory and Manufacturing Progress

In India, joint venture CoSara now has nationwide commercial reach, serving hundreds of labs with 15 CDSCO‑cleared PCR tests and a newly licensed PCR Pro instrument. Expanded distribution across South Asia pushes the addressable market to roughly $13 billion, positioning India as a cornerstone of Co‑Diagnostics’ long‑term growth strategy.

TB Program Advancement Aligned with WHO

Clinical performance studies for the MTB tuberculosis test are slated to begin before month‑end, with possible commercialization in India as early as the end of Q3 2026 if data are supportive. The assay is designed around recent WHO guidance, enabling near point‑of‑care molecular TB testing and tongue swab sampling that could broaden access in resource‑limited settings.

Saudi Arabia Expansion via CoMira JV

In Saudi Arabia, CoMira secured industrial land in Sudair Industrial City, moved forward on facilities and site development, and completed initial funding contributions. These steps set up future localized manufacturing that may unlock procurement advantages and market access across the wider MENA region once operations ramp.

Manufacturing Capacity and Automation Plans

The company’s Utah facility has already produced hundreds of thousands of test cups for R&D and clinical use, demonstrating in‑house manufacturing capability. A next‑gen automated cup line is in development and is expected to boost efficiency by roughly fourfold, cutting manual steps, overhead and potential production errors as volumes grow.

Platform and Pipeline Diversification

Beyond TB and respiratory, management highlighted a broader test and platform pipeline including an HPV program in preclinical or qualification stages and growing placements of the Vector instrument. A cloud‑connected architecture with machine‑learning capabilities and ongoing consumable automation aim to support scalable deployment across multiple use cases.

Very Limited Revenue and Negative Gross Margin

Despite eye‑catching year‑over‑year growth, Q1 revenue of $146,000 could not cover production costs, as cost of revenue reached $194,000 and produced a gross loss of about $48,000. That compares with a gross profit of $29,000 in the prior year, marking a notable deterioration in gross margin as the company invests ahead of scale.

Wider Net Loss and Adjusted EBITDA

The company’s net loss expanded to $9.1 million, or $4.06 per diluted share, versus $7.5 million, or $7.05 per share, in the year‑ago quarter, reflecting heavier spend on development and infrastructure. Adjusted EBITDA loss also worsened to $8.7 million from $7.4 million, signaling that underlying cash burn remains substantial ahead of expected commercialization.

Cash Decline and Need for Additional Capital

Cash and equivalents fell to $8.2 million at quarter‑end from $11.9 million at the end of 2025, a roughly 31% decline that tightens the funding runway. Management was candid that additional capital will likely be required to execute its clinical, regulatory and manufacturing plans, and is weighing equity, debt, partnerships and other funding options.

Rising R&D Spend and Operating Expenses

Operating expenses climbed to $9.2 million from $8.6 million, with research and development rising about 20% to $5.9 million as multiple clinical studies ramped. Sales and marketing and G&A were more modest at $0.5 million and $2.5 million respectively, but the heavier R&D investment is a major driver of both innovation and ongoing cash burn.

COVID Prevalence Impacting Submission Scope

Lower‑than‑expected COVID case rates in the upper respiratory study limited the dataset for that pathogen, forcing the company to narrow its initial submission to Flu A, Flu B and RSV. Management has paused certain clinical infrastructure to preserve flexibility and may seek to add COVID later, illustrating how shifting epidemiology can reshape diagnostics roadmaps.

Strategic Transactions and Build-Out Uncertainty

Management is actively exploring strategic alternatives for CoSara, including a possible SPAC route, but emphasized that talks are ongoing with no agreement in place or assurance of a deal. Meanwhile, manufacturing build‑outs and automation at CoMira and other facilities are progressing but not yet live, leaving some execution and timing risk around when capacity translates into revenue.

Ongoing Losses and Limited Revenue Visibility

Executives acknowledged that Co‑Diagnostics expects to remain in a loss‑making position for the near term, given current revenue levels and heavy investment. With regulatory submissions, manufacturing scale‑up and regional rollouts all on staggered timelines, meaningful revenue visibility appears limited until additional capital is secured and key launches begin to ramp.

Forward-Looking Guidance and Management Outlook

Looking ahead, management is focused on filing the upper respiratory 510(k) for Flu A, Flu B and RSV by Q3 2026, pursuing CLIA‑waived point‑of‑care status and adding COVID later if needed. The company aims to initiate TB clinical performance studies this month with potential India commercialization by late Q3, expand CoSara and CoMira manufacturing, and secure new capital through a mix of financing and partnerships.

Co-Diagnostics’ call left investors balancing tangible operational traction in respiratory, TB and international manufacturing against a strained balance sheet and rising losses. If the company can execute on regulatory filings, scale automated production and secure fresh capital on reasonable terms, the groundwork laid this quarter could eventually translate into more durable revenue and valuation upside.